Last reviewed · How we verify
Intraarterial alteplase
Intraarterial alteplase is a tissue plasminogen activator (tPA) that dissolves blood clots by converting plasminogen to plasmin, which breaks down fibrin in thrombi.
Intraarterial alteplase is a tissue plasminogen activator (tPA) that dissolves blood clots by converting plasminogen to plasmin, which breaks down fibrin in thrombi. Used for Acute ischemic stroke (intraarterial administration), Acute arterial thrombosis.
At a glance
| Generic name | Intraarterial alteplase |
|---|---|
| Also known as | Intraarterial alteplase recombinant tissue plasminogen activator (rTPA), Intraarterial recombinant tissue plasminogen activator (rt-PA) |
| Sponsor | Hospital Clinic of Barcelona |
| Drug class | Fibrinolytic agent / Tissue plasminogen activator (tPA) |
| Target | Plasminogen / Fibrin |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular / Neurology |
| Phase | Phase 3 |
Mechanism of action
Alteplase is a recombinant tissue plasminogen activator that directly activates the fibrinolytic cascade. When administered intraarterially, it achieves high local concentrations at the thrombus site, enabling rapid clot dissolution. This approach is particularly useful in acute ischemic stroke where direct delivery to the cerebral vasculature can restore blood flow to ischemic brain tissue.
Approved indications
- Acute ischemic stroke (intraarterial administration)
- Acute arterial thrombosis
Common side effects
- Intracranial hemorrhage
- Bleeding (systemic)
- Reperfusion injury
- Angioedema
Key clinical trials
- Reperfusion Completion Via Local Arterial Infusion of Tenecteplase After Incomplete Mechanical Thrombectomy (PHASE3)
- Safety and Efficacy of Intra-arterial Tenecteplase for Noncomplete Reperfusion of Intracranial Occlusions (PHASE3)
- Intra-arterial Recombinant Human Tenecteplase Tissue-type Plasminogen Activator (rhTNK-tPA) Thrombolysis for Acute Medium Vessel Occlusion (PHASE2, PHASE3)
- Adjunctive Intra-arterial Tenecteplase Following Mechanical Thrombectomy (ALLY) II Trial (PHASE2, PHASE3)
- Prospective Registry of Endovascular Thrombectomy for eXtra-Large Ischemic Stroke
- Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells in Acute Ischemic Stroke (PHASE1)
- Endovascular Treatment With or Without Preceding Intravenous Tenecteplase (TNK) in Patients With Late-window acUte Ischemic Stroke Due to Middle Cerebral Artery Occlusion (PHASE3)
- Direct Endovascular Treatment Versus Bridging Treatment In Basilar Artery Occlusive Stroke (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intraarterial alteplase CI brief — competitive landscape report
- Intraarterial alteplase updates RSS · CI watch RSS
- Hospital Clinic of Barcelona portfolio CI